• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Anika Therapeutics Inc.

    11/5/25 4:01:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email
    S-8 1 fs8_110425.htm FORM S-8

     As filed with the Securities and Exchange Commission on November 5, 2025

    Registration No. 333-  

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Anika Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   04-3145961
    (State or other jurisdiction of   (I.R.S. Employer Identification No.
    incorporation or organization)    
         
    32 Wiggins Avenue    
    Bedford, Massachusetts   01730
    (Address of principal executive offices)   (Zip code)

     

     

     

    Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

    (Full title of the plan)

     

     

     

    Cheryl R. Blanchard

    President and Chief Executive Officer

    Anika Therapeutics, Inc.

    32 Wiggins Avenue

    Bedford, Massachusetts 01730

    (781) 457-9000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     With copies to:

     

    Michael H. Bison   David Colleran
    Goodwin Procter LLP   Anika Therapeutics, Inc.
    100 Northern Avenue   32 Wiggins Avenue
    Boston, MA 02110   Bedford, MA 01730
    (617) 570-1933   (781) 457-9261

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☒
    Non-accelerated filer ☐ Smaller reporting company ☐
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    STATEMENT OF INCORPORATION BY REFERENCE

     

    This Registration Statement on Form S-8 registers 475,000 additional shares of the Registrant’s common stock, $0.01 par value per share (“Common Stock”), to be issued under the Registrant’s 2017 Omnibus Incentive Plan, as amended (the “Plan”). The additional shares represent an increase in the number of shares of Common Stock reserved for issuance under the Plan, which increase was previously approved by the Registrant’s Board of Directors and subsequently approved by the Registrant’s stockholders on June 20, 2025, at the Registrant’s 2025 Annual Meeting of Stockholders.

     

    The additional shares described above are of the same class as other securities relating to the Plan for which the Registrant previously filed a registration statements on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) on July 7, 2017 (File No. 333-219190), June 21, 2019 (File No. 333-232254), June 19, 2020 (File No. 333-239304), August 6, 2021 (File No. 333-258529), August 5, 2022 (File No. 333-266550), and August 8, 2023 (File No. 333-273812) (together, the “Prior Registration Statements”). The information contained in the Prior Registration Statements, as filed with the Commission, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit Number   Description
         
    4.1   Certificate of Incorporation of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 6, 2018)
    4.2   Bylaws of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on June 6, 2018)
    5.1   Opinion of Goodwin Procter LLP
    23.1   Consent of Deloitte & Touche LLP
    23.2   Consent of Goodwin Procter LLP (included in Exhibit 5.1)
    24.1   Power of Attorney (included on the signature page of this registration statement)
    99.1   Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended on June 18, 2019, June 16, 2020, June 16, 2021, June 8, 2022, June 14, 2023, and June 20, 2025) (incorporated by reference to Exhibit 10.1 on the Current Report on Form 8-K filed on June 24, 2025)
    107   Filing Fee Table

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, Commonwealth of Massachusetts, as of November 5, 2025.

     

     

      ANIKA THERAPEUTICS, INC.
       
      /s/ Cheryl R. Blanchard
      Cheryl R. Blanchard
      President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Cheryl R. Blanchard and David Colleran, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act of 1933 to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

     

    Signature Title Date

     

    /s/ Cheryl R. Blanchard

    Cheryl R. Blanchard

     

     

    Chief Executive Officer, President and Director
    (Principal Executive Officer)

     

     

    November 5, 2025

     

     

    /s/ Stephen D. Griffin

    Stephen D. Griffin

     

     

    Chief Financial Officer and Chief Operating Officer
    (Principal Financial Officer)

     

     

     

    November 5, 2025

     

     

    /s/ Ian McLeod

    Ian McLeod

     

     

    Vice President, Chief Accounting Officer and Treasurer
    (Principal Accounting Officer)

     

     

    November 5, 2025

     

     

    /s/ John B. Henneman, III

    John B. Henneman, III

     

     

    Director and Chair of the Board of Directors

     

     

    November 5, 2025

     

     

    /s/ Joseph H. Capper

    Joseph H. Capper

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ Sheryl L. Conley

    Sheryl L. Conley

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ Gary P. Fischetti

    Gary P. Fischetti

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ William R. Jellison

    William R. Jellison

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ Glenn R. Larsen

    Glenn R. Larsen

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ Stephen O. Richard

    Stephen O. Richard

     

     

    Director

     

     

    November 5, 2025

     

     

    /s/ Susan L. N. Vogt

    Susan L. N. Vogt

     

     

    Director

     

     

    November 5, 2025

     

     

     

     

     

    Get the next $ANIK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study

    BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTRACK clinical trial evaluating Hyalofast. On October 31, 2025, Anika submitted the third and final module of its Hyalofast PMA to the U.S. Food and Drug Administration (FDA). The PMA includes FastTRA

    11/5/25 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a

    10/23/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Vogt Susan L N was granted 14,164 shares, increasing direct ownership by 39% to 50,213 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:14:37 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Richard Stephen was granted 14,164 shares, increasing direct ownership by 42% to 47,871 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:13:40 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Larsen Glenn R. was granted 14,164 shares, increasing direct ownership by 39% to 50,258 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:13:04 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/7/25 6:06:11 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Anika Therapeutics Inc.

    S-8 - Anika Therapeutics, Inc. (0000898437) (Filer)

    11/5/25 4:01:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Anika Therapeutics Inc.

    10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

    11/5/25 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    Anika Enters into Cooperation Agreement with Caligan Partners

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

    5/28/24 4:05:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Announces CFO Transition

    BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

    5/8/24 4:08:54 PM ET
    $ANIK
    $VSEC
    Medical/Dental Instruments
    Health Care
    Military/Government/Technical
    Consumer Discretionary

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a

    10/23/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Second Quarter 2025 Financial Results

    Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July

    7/30/25 7:05:25 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care